Sudeep Pharma Ltd
Incorporated in 1989, Sudeep Pharma Limited is a manufacturer of pharmaceutical excipients, food-grade minerals, and specialty nutrition ingredients serving over 100 countries.[1]
- Market Cap ₹ 12,066 Cr.
- Current Price ₹ 1,068
- High / Low ₹ 1,378 / 524
- Stock P/E 64.1
- Book Value ₹ 84.8
- Dividend Yield 0.14 %
- ROCE 28.2 %
- ROE 25.2 %
- Face Value ₹ 1.00
Pros
- Company has delivered good profit growth of 39.0% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 31.8%
Cons
- Stock is trading at 12.6 times its book value
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|
| 123 | 215 | 343 | 429 | 459 | 502 | 642 | 710 | |
| 98 | 171 | 276 | 338 | 276 | 310 | 419 | 459 | |
| Operating Profit | 25 | 44 | 67 | 90 | 183 | 192 | 223 | 251 |
| OPM % | 21% | 20% | 20% | 21% | 40% | 38% | 35% | 35% |
| 3 | 3 | 7 | 9 | 6 | 9 | 28 | 25 | |
| Interest | 1 | 1 | 2 | 6 | 5 | 7 | 8 | 8 |
| Depreciation | 3 | 4 | 5 | 8 | 9 | 11 | 15 | 17 |
| Profit before tax | 25 | 43 | 69 | 86 | 175 | 183 | 228 | 250 |
| Tax % | 27% | 22% | 27% | 28% | 24% | 24% | 24% | |
| 18 | 33 | 50 | 62 | 133 | 139 | 174 | 189 | |
| EPS in Rs | 2.15 | 3.97 | 5.97 | 7.42 | 15.86 | 14.27 | 15.31 | 16.68 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 24% |
| 3 Years: | 14% |
| TTM: | 27% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 39% |
| 3 Years: | 40% |
| TTM: | 26% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 32% |
| 3 Years: | 32% |
| Last Year: | 25% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 1 | 1 | 1 | 1 | 1 | 10 | 11 | 11 |
| Reserves | 80 | 113 | 162 | 222 | 355 | 481 | 872 | 946 |
| 20 | 31 | 84 | 83 | 78 | 140 | 150 | 189 | |
| 30 | 67 | 97 | 113 | 80 | 86 | 141 | 182 | |
| Total Liabilities | 131 | 213 | 344 | 420 | 514 | 717 | 1,174 | 1,329 |
| 60 | 68 | 137 | 158 | 180 | 189 | 337 | 524 | |
| CWIP | 8 | 24 | 8 | 26 | 45 | 88 | 185 | 54 |
| Investments | 6 | 19 | 0 | 3 | 0 | 0 | 0 | 0 |
| 57 | 102 | 199 | 232 | 289 | 439 | 652 | 751 | |
| Total Assets | 131 | 213 | 344 | 420 | 514 | 717 | 1,174 | 1,329 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| 10 | 35 | -3 | 48 | 66 | 49 | 70 | |
| -22 | -40 | -38 | -50 | -49 | -79 | -327 | |
| 12 | 13 | 51 | -10 | -13 | 53 | 247 | |
| Net Cash Flow | -0 | 8 | 10 | -11 | 4 | 23 | -10 |
| Free Cash Flow | 1 | 24 | -77 | 1 | 13 | -15 | -49 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 62% | 104% | 22% | 78% | 60% | 47% | 56% |
Ratios
Consolidated / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 90 | 94 | 114 | 80 | 115 | 135 | 129 |
| Inventory Days | 77 | 79 | 104 | 142 | 147 | 309 | 356 |
| Days Payable | 70 | 79 | 76 | 77 | 112 | 145 | 113 |
| Cash Conversion Cycle | 97 | 93 | 142 | 145 | 150 | 298 | 372 |
| Working Capital Days | 46 | 13 | 30 | 92 | 99 | 144 | 175 |
| ROCE % | 36% | 36% | 33% | 49% | 36% | 28% |
Insights
In beta| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Installed Capacity MTPA |
|
|||
| Number of Countries Served count |
||||
| Permanent Employees count |
||||
| R&D Expenses as % of Revenue from Operations % |
||||
| Capacity Utilization % |
||||
| Specialty Ingredients Sales Volume MT |
||||
| Total Sales Volume MT |
||||
| Battery Materials - Active Customers count |
||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
- Audio recording of the 29 October 2026 earnings call uploaded.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
- Submission of Newspaper Advertisement for unaudited Financials for the Quarter and Half Year ended 30th September 2026.
- Announcement under Regulation 30 (LODR)-Investor Presentation
- Unaudited Financial Results For The Quarter And Half Year Ended 30Th September 2026
-
Board Meeting Outcome for Outcome Of Board Meeting Held On 28Th October 2026
- Board approved Q2 FY27 results on 28 Oct 2026; consolidated profit rose to ₹5,181.11 lakh.
Concalls
-
Oct 2026PPT REC
-
Aug 2026Transcript PPT REC
-
Aug 2026PPT
-
Aug 2026PPT
-
May 2026Transcript PPT REC
-
Feb 2026Transcript PPT
-
Dec 2025Transcript PPT
Company Overview[1]
Sudeep Pharma Limited is a leading manufacturer of excipients and specialty ingredients catering to the pharmaceutical, food, and nutrition industries. The company has evolved from producing basic excipients to offering a broad portfolio of over 100 products, serving more than 1,100 customers globally. Its mineral-based ingredients, including calcium, zinc, iron, and magnesium salts, are widely used in formulations across health, nutrition, and food applications.